Da	te: <u>September 13, 2021</u>					
	ur Name: <u>Amanda Leit</u>					
	Manuscript Title:Assessing the Association of Diabetes with Lung Cancer Risk					
Ma	nuscript number (if known)	):TLCR	-21-601-CL			
rela pai to	ated to the content of your ries whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment  If you are in doubt about whether to list a			
The			ips/activities/interests as they relate to the <u>current</u>			
to	• •	ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.			
	tem #1 below, report all sup time frame for disclosure is	• •	ed in this manuscript without time limit. For all other items,			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initia	al planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone				
		T: f	126 months			
2	Grants or contracts from	Time frame: pas X None	t 56 months			
_	any entity (if not indicated in item #1 above).					
3	Royalties or licenses	XNone				

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co		
Ple	ase place an "X" next to the	following statement to in	dicate your agreement:

Dat	e: September 9, 2021		
Υοι	ır Name: <u>Antonios Ch</u>	arokopos	
Ma	nuscript Title:Asse	essing the Association o	of Diabetes with Lung Cancer Risk
Ma	nuscript number (if known)	:TLCR	-21-601-CL
rela par to t	ated to the content of your ties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current
to t me In i	the epidemiology of hypertodication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	e defined broadly. For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
-	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 26 months
	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months
3	Royalties or licenses	XNone	

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co		
Ple	ase place an "X" next to the	following statement to in	dicate your agreement:

Da	te: September 9, 2021		
	ur Name: <u>Stacyann Bai</u>		
Ma	nuscript Title:Asse	essing the Association of	f Diabetes with Lung Cancer Risk
Ma	nuscript number (if known)	):TLCR-	-21-601-CL
rel	ated to the content of your	manuscript. "Related" me	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment
to		necessarily indicate a bias.	If you are in doubt about whether to list a
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to		ension, you should declare	<u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	item #1 below, report all su e time frame for disclosure i	• •	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	nlanning of the work
		Time trame. Since the finda	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co		
Ple	ase place an "X" next to the	following statement to in	dicate your agreement:

Date: September 10,	ate: September 10, 2021		
Name: Emily J. Galla	Name: Émily J. Gallagher		
Manuscript Title:	Assessing th	e Association of Diabetes with Lung Cancer Risk	
Manuscript number	(if known):	TLCR-21-601-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	Novartis	Advisory board
		Seattle Genetics	Consulting honorarium
		SynDevX	Consulting honorarium

5	Payment or honoraria for	Infomedica	Payment for educational lecture
	lectures, presentations, speakers bureaus,	American Diabetes Association	Payment for educational lecture
	manuscript writing or educational events		
6	Payment for expert	_x_None	
	testimony		
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or	_x_None	
	pending		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_x_None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_None	
12	Receipt of equipment,	x None	
12	materials, drugs, medical	X_NOTIC	
	writing, gifts or other services		
13	Other financial or non-	_x_None	
	financial interests		

### Please summarize the above conflict of interest in the following box:

No conflict of interest directly related to this work.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: September 9. 2021				
Name: Fred R. Hirsch	Name: Fred R. Hirsch			
Manuscript Title:	Assessing the Association of Diabetes with Lung Cancer Risk			
Manuscript number (if I	known): TLCR-21-601-CL			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	Bristol-Myers Squibb,	For all; Scientific advisory boards.
		Merck, Amgen,	
		AstraZeneca/Daiichi,	

		Sanofi/Regeneron, Novartis, OncoCyte, Genentech	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca, Roche	For both: Educational lecture/presentation
6	Payment for expert testimony	Gehrson Lehrman Group (GLG)	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

# Please summarize the above conflict of interest in the following box:

No conflict of interest directly related to this work.

X_ I certify that I have answered ever form.	ery question and have not altered the	wording of any of the questions on this

Please place an "X" next to the following statement to indicate your agreement:

Da	te: <u>September 13, 2021</u>		
	ur Name: <u>Derek LeRoit</u>		
		_	f Diabetes with Lung Cancer Risk
Ma	nuscript number (if known)	:TLCR	-21-601-CL
rel pa to	ated to the content of your ries whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current
to me	the epidemiology of hypertodication, even if that medic	ension, you should declare cation is not mentioned in	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
	tem #1 below, report all su time frame for disclosure i	• •	ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
<u>)</u>	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
}	Royalties or licenses	XNone	

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co		
Ple	ase place an "X" next to the	following statement to in	dicate your agreement:

Date: September 10,	2021		
Name: Juan P. Wisni	vesky		
Manuscript Title:	Assessing the	Association of Diabetes with Lung Cancer Risk	
Manuscript number	(if known):	TLCR-21-601-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Sanofi, Arnold Consultants	Research grants
3	Royalties or licenses	xNone	
4	Consulting fees	Banook, GSK, Sanofi, Atea Pharmaceutical	Consulting honorarium

5	Payment or honoraria for	_x_None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	_x_None
	testimony	
7	Support for attending meetings and/or travel	xNone
8	Patents planned, issued or	_x_None
	pending	
9	Participation on a Data	_x_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_x_None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_x_None
12	Receipt of equipment,	_x_None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	_x_None
	financial interests	

## Please summarize the above conflict of interest in the following box:

No conflict of interest directly related to this work.	

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.